Publications

  1. Hypoimmune cells resist rejection in monkeys. Borrero Borrego A, Gill SI. Nature Biotechnology. 2023 Oct 23. https://doi.org/10.1038/s41587-023-02013-1.
  2. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Wellhausen N, O’Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, & Gill SI. Sci Transl Med. 2023 Aug31; eadi1145. doi:10.1126/scitranslmed.adi1145. Online ahead of print. PMID: 37651540.
  3. Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. Hatch RV, Freyer CW, Carulli A, Redline G, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz KW, Stadtmauer EA, Loren AW. J Oncol Pharm Pract. 2022 Jun;28(4):892-897. doi: 10.1177/10781552221080710. Epub 2022 Feb 22. PubMed PMID: 35191732.
  4. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard I, Carroll MP, Frey NV, Hexner E, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Jordan Bruno X, Hwang WT, Margolis D, Pratz KW.  Blood Adv. 2022 May 4;. doi: 10.1182/bloodadvances.2022007265. [Epub ahead of print] PubMed PMID: 35507945.
  5.  Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease. Freyer CW, Gier S, Carulli A, Gill SI, Hexner EO, Loren AW, Martin ME, Porter DL.Am J Hematol. 2022 Apr 12;. doi: 10.1002/ajh.26568. [Epub ahead of print] PubMed PMID: 35413140.
  6. Epigenetic engineering empowers T cells. Tandel JV, Gill SI.  Blood. 2022 Apr 7;139(14):2091-2092. doi: 10.1182/blood.2021015016. PubMed PMID: 35389443.
  7. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. . Nat Med. 2022 Apr;28(4):713-723. doi: 10.1038/s41591-022-01702-9. Epub 2022 Mar 14. PubMed PMID: 35288695.
  8. Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia.  Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Blood Adv. 2022 Mar 29;. doi: 10.1182/bloodadvances.2022007317. [Epub ahead of print] PubMed PMID: 35349631.
  9. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Graveno ME, Carulli A, Freyer CW, Mangan BL, Nietupski R, Loren AW, Frey NV, Porter DL, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Babushok DV, Pratz KW.  Leuk Lymphoma. 2022 Mar 8;:1-6. doi: 10.1080/10428194.2022.2042688. [Epub ahead of print] PubMed PMID: 35259056.
  10. Rapid manufacturing of non-activated potent CAR T cells. Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA, Reddy S, Bushman FD, Gill SI, O'Doherty U, O'Connor RS, Milone MC.  Nat Biomed Eng. 2022 Feb;6(2):118-128. doi: 10.1038/s41551-021-00842-6. Epub 2022 Feb 21. PubMed PMID: 35190680; PubMed Central PMCID: PMC8860360.
  11. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideFreyer CW, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, Babushok D, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz K, Smith J, Stadtmauer EA, Loren AW. Leuk Lymphoma. 2022 Feb 20;:1-9. doi: 10.1080/10428194.2022.2042686. [Epub ahead of print] PubMed PMID: 35188052.
  12. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH.  Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2. PubMed PMID: 35110735.
  13. Wellhausen N, Agarwal S, Rommel PC, Gill SI, June CH. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. Curr Opin Immunol. 2022 Feb;74:76-84. doi: 10.1016/j.coi.2021.10.008. Epub 2021 Nov 16. Review. PubMed PMID: 34798542.
  14. AlJanahi AA, Lazzarotto CR, Chen S, Shin TH, Cordes S, Fan X, Jabara I, Zhou Y, Young DJ, Lee BC, Yu KR, Li Y, Toms B, Tunc I, Hong SG, Truitt LL, Klermund J, Andrieux G, Kim MY, Cathomen T, Gill S, Tsai SQ, Dunbar CE. Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques. Mol Ther. 2022 Jan 5;30(1):209-222. doi: 10.1016/j.ymthe.2021.06.016. Epub 2021 Jun 24. PubMed PMID: 34174439; PubMed Central PMCID: PMC8753565.
  15. Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol. 2021;12:783305. doi: 10.3389/fimmu.2021.783305. eCollection 2021. Review. PubMed PMID: 34899748; PubMed Central PMCID: PMC8652144.
  16. Lu C, Glisovic-Aplenc T, Bernt KM, Nestler K, Cesare J, Cao L, Lee H, Fazelinia H, Chinwalla A, Xu Y, Shestova O, Xing Y, Gill S, Li M, Garcia B, Aplenc R. Longitudinal Large-Scale Semiquantitative Proteomic Data Stability Across Multiple Instrument Platforms. J Proteome Res. 2021 Nov 5;20(11):5203-5211. doi: 10.1021/acs.jproteome.1c00624. Epub 2021 Oct 20. PubMed PMID: 34669412.
  17. Freyer CW, Fradley M, Madnick D, Carver JR, Frey NV, Gill SI, Ky B, Luger SM, Martin ME, McCurdy SR, O'Quinn R, Perl AE, Stadtmauer EA, Loren AW. Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 Nov;27(11):934.e1-934.e6. doi: 10.1016/j.jtct.2021.07.025. Epub 2021 Jul 30. PubMed PMID: 34339867.
  18. Gupta A, Gill S. CAR-T cell persistence in the treatment of leukemia and lymphoma. Leuk Lymphoma. 2021 Nov;62(11):2587-2599. doi: 10.1080/10428194.2021.1913146. Epub 2021 Apr 19. Review. PubMed PMID: 33872091.
  19. Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22. PubMed PMID: 34156898; PubMed Central PMCID: PMC8500663.
  20. Lesch S, Gill S. The promise and perils of immunotherapy. Blood Adv. 2021 Sep 28;5(18):3709-3725. doi: 10.1182/bloodadvances.2021004453C. Review. PubMed PMID: 34581774; PubMed Central PMCID: PMC8945582.
  21. Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22. PubMed PMID: 33888899; PubMed Central PMCID: PMC8451032.
  22. Freyer CW, Gier S, Moyer ME, Berryman N, Carulli A, Ganetsky A, Timlin C, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy S, Perl AE, Smith J, Luger SM, Stadtmauer EA, Porter DL. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Transplant Cell Ther. 2021 May;27(5):431.e1-431.e8. doi: 10.1016/j.jtct.2021.01.028. Epub 2021 Feb 5. PubMed PMID: 33965188.
  23. Gill S, Brudno JN. CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-20. doi: 10.1200/EDBK_320085. PubMed PMID: 33989023.
  24. Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Res. 2021 Mar 1;81(5):1201-1208. doi: 10.1158/0008-5472.CAN-20-2990. Epub 2020 Nov 17. Review. PubMed PMID: 33203697.
  25. Gill S. DARTs point the way forward in AML. Blood. 2021 Feb 11;137(6):720-721. doi: 10.1182/blood.2020009020. PubMed PMID: 33570611.
  26. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2021 Feb 1;181(2):195-202. doi: 10.1001/jamainternmed.2020.6319. PubMed PMID: 33001138; PubMed Central PMCID: PMC7527945.
  27. Mackenzie S, Gill S. Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship. Leuk Lymphoma. 2020 Dec;61(13):3035-3037. doi: 10.1080/10428194.2020.1830392. Epub 2020 Oct 25. PubMed PMID: 33100079.
  28. Beyar-Katz O, Gill S. Advances in chimeric antigen receptor T cells. Curr Opin Hematol. 2020 Nov;27(6):368-377. doi: 10.1097/MOH.0000000000000614. Review. PubMed PMID: 32925186.
  29. Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leuk Lymphoma. 2020 Sep;61(9):2200-2207. doi: 10.1080/10428194.2020.1765239. Epub 2020 Jun 1. PubMed PMID: 32482107.
  30. Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Sep 1;38(25):2862-2871. doi: 10.1200/JCO.19.03237. Epub 2020 Apr 16. PubMed PMID: 32298202; PubMed Central PMCID: PMC8265376.
  31. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947-953. doi: 10.1038/s41587-020-0462-y. Epub 2020 Mar 23. PubMed PMID: 32361713; PubMed Central PMCID: PMC7883632.
  32. Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482. PubMed PMID: 32589727; PubMed Central PMCID: PMC7362378.
  33. Finck A, Gill SI, June CH. Cancer immunotherapy comes of age and looks for maturity. Nat Commun. 2020 Jul 3;11(1):3325. doi: 10.1038/s41467-020-17140-5. Review. PubMed PMID: 32620755; PubMed Central PMCID: PMC7335079.
  34. Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol. 2020 Jul;95(7):792-798. doi: 10.1002/ajh.25808. Epub 2020 May 4. PubMed PMID: 32242967.
  35. Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol. 2020;10:697. doi: 10.3389/fonc.2020.00697. eCollection 2020. Review. PubMed PMID: 32435621; PubMed Central PMCID: PMC7218049.
  36. Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discov. 2020 Apr;10(4):552-567. doi: 10.1158/2159-8290.CD-19-0813. Epub 2020 Jan 30. PubMed PMID: 32001516; PubMed Central PMCID: PMC7416790.
  37. Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill SI. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. Blood. 2020 Feb 13;135(7):505-509. doi: 10.1182/blood.2019001859. PubMed PMID: 31703119; PubMed Central PMCID: PMC7019191.
  38. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9. PubMed PMID: 31815579; PubMed Central PMCID: PMC8312030.
  39. Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest. 2020 Feb 3;130(2):673-685. doi: 10.1172/JCI130144. PubMed PMID: 31845905; PubMed Central PMCID: PMC6994131.
  40. Gill SI. How close are we to CAR T-cell therapy for AML?. Best Pract Res Clin Haematol. 2019 Dec;32(4):101104. doi: 10.1016/j.beha.2019.101104. Epub 2019 Oct 18. Review. PubMed PMID: 31779970.
  41. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15. PubMed PMID: 31092900; PubMed Central PMCID: PMC8268756.
  42. Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S. Bispecific Antibodies in the Treatment of Hematologic Malignancies. Clin Pharmacol Ther. 2019 Oct;106(4):781-791. doi: 10.1002/cpt.1396. Epub 2019 Mar 29. Review. PubMed PMID: 30770546; PubMed Central PMCID: PMC6766786.
  43. Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?. Haematologica. 2019 Jul;104(7):1302-1308. doi: 10.3324/haematol.2018.208751. Epub 2019 Jun 20. PubMed PMID: 31221785; PubMed Central PMCID: PMC6601074.
  44. Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019 May 30;68(12):2003-2009. doi: 10.1093/cid/ciy822. PubMed PMID: 30256954; PubMed Central PMCID: PMC6541731.
  45. Cummins KD, Gill S. Will CAR T cell therapy have a role in AML? Promises and pitfalls. Semin Hematol. 2019 Apr;56(2):155-163. doi: 10.1053/j.seminhematol.2018.08.008. Epub 2018 Aug 29. Review. PubMed PMID: 30926092; NIHMSID:NIHMS1506857.
  46. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18. PubMed PMID: 30576834; PubMed Central PMCID: PMC8335749.
  47. Petty NE, Gill SI. 21st Century FOX: Toward Gene Therapy for the Regulatory T Cell Deficiency Syndrome IPEX. Cell Stem Cell. 2019 Feb 7;24(2):208-209. doi: 10.1016/j.stem.2018.12.016. PubMed PMID: 30735648.
  48. Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant. 2019 Feb;54(2):212-217. doi: 10.1038/s41409-018-0236-z. Epub 2018 May 24. PubMed PMID: 29795429.
  49. Beyar-Katz O, Gill S. Novel Approaches to Acute Myeloid Leukemia Immunotherapy. Clin Cancer Res. 2018 Nov 15;24(22):5502-5515. doi: 10.1158/1078-0432.CCR-17-3016. Epub 2018 Jun 14. Review. PubMed PMID: 29903894.
  50. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1. PubMed PMID: 30275568; PubMed Central PMCID: PMC6511988.
  51. Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20. PubMed PMID: 29925499.
  52. Cummins KD, Gill S. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leuk Lymphoma. 2018 Jul;59(7):1539-1553. doi: 10.1080/10428194.2017.1375107. Epub 2017 Sep 13. Review. PubMed PMID: 28901790.
  53. Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31. PubMed PMID: 29856956; PubMed Central PMCID: PMC6003425.
  54. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c. PubMed PMID: 29634689.
  55. Hosoya H, Levine J, Abt P, Henry D, Porter DL, Gill S. Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Adv. 2018 Mar 13;2(5):575-585. doi: 10.1182/bloodadvances.2017012500. Review. PubMed PMID: 29535106; PubMed Central PMCID: PMC5851417.
  56. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. PubMed PMID: 29431743; PubMed Central PMCID: PMC6029618.
  57. Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight. 2018 Feb 22;3(4). doi: 10.1172/jci.insight.94952. eCollection 2018 Feb 22. PubMed PMID: 29467322; PubMed Central PMCID: PMC5916241.
  58. Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S. Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2. PubMed PMID: 28576927; PubMed Central PMCID: PMC5628114.
  59. Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH. Improved surfaceome coverage with a label-free nonaffinity-purified workflow. Proteomics. 2017 Apr;17(7). doi: 10.1002/pmic.201600344. Epub 2017 Mar 6. PubMed PMID: 28116781; PubMed Central PMCID: PMC5518111.
  60. Kenderian SS, Porter DL, Gill S. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol Blood Marrow Transplant. 2017 Feb;23(2):235-246. doi: 10.1016/j.bbmt.2016.09.002. Epub 2016 Sep 13. Review. PubMed PMID: 27638367; PubMed Central PMCID: PMC5237606.
  61. Gill S. Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy. Sci Transl Med. 2017 Feb 1;9(375). doi: 10.1126/scitranslmed.aam6051. Epub 2017 Feb 1. PubMed PMID: 28148843.
  62. Gill S. CAR T cells engage in anticancer martial arts. Sci Transl Med. 2017 Jan 18;9(373). doi: 10.1126/scitranslmed.aal4996. PubMed PMID: 28100838.
  63. Gill S. Chimeric antigen receptor T cell therapy in AML: How close are we?. Best Pract Res Clin Haematol. 2016 Dec;29(4):329-333. doi: 10.1016/j.beha.2016.10.004. Epub 2016 Oct 18. Review. PubMed PMID: 27890255; PubMed Central PMCID: PMC5131522.
  64. Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29. PubMed PMID: 27571406; PubMed Central PMCID: PMC5096828.
  65. Gill S. Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. Curr Hematol Malig Rep. 2016 Aug;11(4):318-25. doi: 10.1007/s11899-016-0330-5. Review. PubMed PMID: 27136938; PubMed Central PMCID: PMC5018307.
  66. Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey NV. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. Am J Hematol. 2016 Jun;91(4):426-9. doi: 10.1002/ajh.24308. PubMed PMID: 26820493.
  67. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27. PubMed PMID: 26819453.
  68. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016 May;30(3):157-67. doi: 10.1016/j.blre.2015.10.003. Epub 2015 Nov 6. Review. PubMed PMID: 26574053.
  69. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26. PubMed PMID: 26813675; PubMed Central PMCID: PMC4778162.
  70. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29. PubMed PMID: 26516065; PubMed Central PMCID: PMC4670800.
  71. Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27. PubMed PMID: 25721896; PubMed Central PMCID: PMC4644600.
  72. Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8. PubMed PMID: 26056179; PubMed Central PMCID: PMC4500833.
  73. Ruella M, Gill S. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther. 2015 Jun;15(6):761-6. doi: 10.1517/14712598.2015.1009888. Epub 2015 Feb 2. PubMed PMID: 25640460.
  74. Gill S. The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse. Clin Cancer Res. 2015 May 1;21(9):1981-3. doi: 10.1158/1078-0432.CCR-14-2930. Epub 2015 Feb 2. PubMed PMID: 25645863.
  75. Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM. Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition. Biol Blood Marrow Transplant. 2015 Apr;21(4):768-71. doi: 10.1016/j.bbmt.2014.12.005. Epub 2014 Dec 24. PubMed PMID: 25543093.
  76. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015 Jan;263(1):68-89. doi: 10.1111/imr.12243. Review. PubMed PMID: 25510272.
  77. Kenderian SS, Ruella M, Gill S, Kalos M. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4. PubMed PMID: 25371415.
  78. Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10. PubMed PMID: 25016197; PubMed Central PMCID: PMC4194246.
  79. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. PubMed PMID: 24596416; PubMed Central PMCID: PMC3983612.
  80. Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther. 2014 Jan;14(1):37-49. doi: 10.1517/14712598.2014.860442. Epub 2013 Nov 21. Review. PubMed PMID: 24261468.
  81. Ganetsky A, Kucharczuk C, Del Percio S, Frey N, Gill S. Spontaneous subcapsular splenic hematoma associated with filgrastim in a patient undergoing allogeneic hematopoietic stem cell transplantation. Ann Pharmacother. 2013 May;47(5):e22. doi: 10.1345/aph.1S005. Epub 2013 Apr 12. PubMed PMID: 23585644.
  82. Gill S, Kalos M. T cell-based gene therapy of cancer. Transl Res. 2013 Apr;161(4):365-79. doi: 10.1016/j.trsl.2012.11.002. Epub 2012 Dec 11. Review. PubMed PMID: 23246626.
  83. Gill S, Porter DL. Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. Annu Rev Med. 2013;64:101-17. doi: 10.1146/annurev-med-121411-103452. Epub 2012 Oct 29. Review. PubMed PMID: 23121181.
  84. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin RS. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012 Jun 14;119(24):5758-68. doi: 10.1182/blood-2012-03-415364. Epub 2012 Apr 27. PubMed PMID: 22544698; PubMed Central PMCID: PMC3382935.
  85. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044. PubMed PMID: 20813259; PubMed Central PMCID: PMC2943345.
  86. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010 May 27;115(21):4293-301. doi: 10.1182/blood-2009-05-222190. Epub 2010 Mar 16. PubMed PMID: 20233969; PubMed Central PMCID: PMC2879101.
  87. Benjamin JE, Gill S, Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol. 2010 Mar;22(2):130-7. doi: 10.1097/CCO.0b013e328335a559. Review. PubMed PMID: 20010294; PubMed Central PMCID: PMC2880497.
  88. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, Carney DA, Ritchie DS, Davies JM, Seymour JF. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009 Oct;147(1):83-8. doi: 10.1111/j.1365-2141.2009.07835.x. Epub 2009 Aug 19. PubMed PMID: 19694718.
  89. Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009 Jul;15(7):765-76. doi: 10.1016/j.bbmt.2009.01.019. Epub 2009 Apr 2. Review. PubMed PMID: 19539207; PubMed Central PMCID: PMC2884143.
  90. Gill S, Seymour JF. What is the real risk of central nervous system involvement in mantle cell lymphoma?. Leuk Lymphoma. 2008 Dec;49(12):2237-9. doi: 10.1080/10428190802495855. PubMed PMID: 19052969.
  91. Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol. 2008 Sep;87(9):727-34. doi: 10.1007/s00277-008-0488-6. Epub 2008 Apr 10. PubMed PMID: 18401583.
  92. Gill S, Hicks RJ, Seymour JF. What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. Leuk Lymphoma. 2008 Sep;49(9):1653-6. doi: 10.1080/10428190802311433. Review. PubMed PMID: 18798097.
  93. Gill S, Wolf M, Prince HM, Januszewicz H, Ritchie D, Hicks RJ, Seymour JF. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65. doi: 10.3816/CLM.2008.n.019. PubMed PMID: 18650179.
  94. Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma. 2008 Mar;49(3):398-409. doi: 10.1080/10428190701851364. Review. PubMed PMID: 18297516.
  95. Gill S, Shapiro J, Westerman D, Prince HM. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma. J Clin Oncol. 2007 Oct 1;25(28):4493-4. doi: 10.1200/JCO.2007.12.9338. PubMed PMID: 17906211.